Potsdam-based Signature Dx plans to launch by the fourth quarter of this year two array-based in vitro diagnostics for colorectal cancer. The company will first launch the tests in Europe and intends to seek US regulatory approval at an unspecified time in the future.
The agency added new pharmacogenetic information to the label of the metastatic colorectal cancer treatment irinotecan regarding heightened risk for grade 4 neutropenia in patients homozygous and heterozygous for the UGT1A1*28 allele.
Researchers from Ghent University and the National University of Ireland have identified and validated a panel of six microRNAs ideal for use as reference genes in PCR-based miRNA expression analysis in colorectal cancer.
In the May issue of Cancer Prevention Research, Steven Lipkin and colleagues reported that in colon cancer cell lines, the protective effect against colorectal cancer was stronger in cells with a particular SNP in the HMGCR gene.